This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Prognostic characteristics of duodenal gastrointestinal stromal tumours. BJS 2015; 102: 959-964.

Published: 18th May 2015

Authors: Q. Zhang, C.‐H. Shou, J.‐R. Yu, W.‐L. Yang, X.‐S. Liu, H. Yu et al.

Background

This study evaluated the clinical characteristics, surgical procedures and prognosis of duodenal gastrointestinal stromal tumours (GISTs).

Method

Patients with a diagnosis of primary duodenal GIST treated between January 2000 and December 2012 were analysed. Patients with gastric and small intestinal GISTs were chosen as control groups according to the following parameters: age, tumour size, mitotic index and adjuvant imatinib therapy. Operative procedures for patients with duodenal GIST included pancreaticoduodenectomy or limited resection. Disease‐free survival (DFS) was calculated using Kaplan–Meier analysis.

Results

Some 71 patients with duodenal, 71 with gastric and 70 with small intestinal GISTs were included in the study. DFS of patients with duodenal GIST was shorter than that of patients with gastric GIST (3‐year DFS 84 versus 94 per cent; hazard ratio (HR) 3.67, 95 per cent c.i. 1.21 to 11.16; P = 0.014), but was similar to that of patients with small intestinal GIST (3‐year DFS 84 versus 81 per cent; HR 0.75, 0.37 to 1.51; P = 0.491). Patients who underwent pancreaticoduodenectomy were older, and had larger tumours and a higher mitotic index than patients who had limited resection. The 3‐year DFS was 93 per cent among patients who had limited resection compared with 64 per cent for those who underwent PD (HR 0.18, 0.06 to 0.59; P = 0.001).

Conclusion

The prognosis of duodenal GISTs is similar to that of small intestinal GISTs.

Full text

You may also be interested in

Randomized clinical trial

Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial).

Authors: K. Misawa, Y. Mochizuki, M. Sakai, H. Teramoto, D. Morimoto, H. Nakayama et al.

Randomized clinical trial

Long‐term follow‐up of two randomized trials comparing laparoscopic Nissen 360° with anterior 90° partial fundoplication.

Authors: R. J. Hopkins, T. Irvine, G. G. Jamieson, P. G. Devitt, D. I. Watson

Randomized clinical trial

Health‐related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial). BJS 2019; 106: 1452-1463.

Authors: B. Sunde, F. Klevebro, A. Johar, G. Johnsen, A.‐B. Jacobsen, N. I. Glenjen et al.

Original article

Morphological lymphocytic reaction, patient prognosis and PD‐1 expression after surgical resection for oesophageal cancer. BJS 2019; 106: 1352-1361.

Authors: Y. Baba, T. Yagi, K. Kosumi, K. Okadome, D. Nomoto, K. Eto et al.

Original article

Quality of life from a randomized trial of laparoscopic or open liver resection for colorectal liver metastases. BJS 2019; 106: 1372-1380.

Authors: Å. A. Fretland, V. J. Dagenborg, G. M. Waaler Bjørnelv, D. L. Aghayan, A. M. Kazaryan, L. Barkhatov et al.

Original article

Effect of neoadjuvant chemoradiation on preoperative pulmonary physiology, postoperative respiratory complications and quality of life in patients with oesophageal cancer. BJS 2019; 106: 1341-1351.

Authors: J. A. Elliott, L. O'Byrne, G. Foley, C. F. Murphy, S. L. Doyle, S. King et al.

Original article

Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro‐oesophageal junction.

Authors: W. H. Allum, E. C. Smyth, J. M. Blazeby, H. I. Grabsch, S. M. Griffin, S. Rowley et al.

Systematic review

Meta‐analysis of randomized clinical trials of early versus delayed cholecystectomy for mild gallstone pancreatitis. BJS 2019; 106: 1442-1451.

Authors: N. Moody, A. Adiamah, F. Yanni, D. Gomez

Article

Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy.

Authors: J. X. Lin, C. Yoon, J. Desiderio, B. C. Yi, P. Li, C. H. Zheng et al.

Prognostic characteristics of duodenal gastrointestinal stromal tumours. BJS 2015; 102: 959-964.

Background

Method

Results

Conclusion

You may also be interested in

Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial).

Long‐term follow‐up of two randomized trials comparing laparoscopic Nissen 360° with anterior 90° partial fundoplication.

Health‐related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial). BJS 2019; 106: 1452-1463.

Morphological lymphocytic reaction, patient prognosis and PD‐1 expression after surgical resection for oesophageal cancer. BJS 2019; 106: 1352-1361.

Quality of life from a randomized trial of laparoscopic or open liver resection for colorectal liver metastases. BJS 2019; 106: 1372-1380.

Effect of neoadjuvant chemoradiation on preoperative pulmonary physiology, postoperative respiratory complications and quality of life in patients with oesophageal cancer. BJS 2019; 106: 1341-1351.

Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro‐oesophageal junction.

Meta‐analysis of randomized clinical trials of early versus delayed cholecystectomy for mild gallstone pancreatitis. BJS 2019; 106: 1442-1451.

Screening for gastric cancer using exhaled breath samples.

Bile acid changes after metabolic surgery are linked to improvement in insulin sensitivity.

Routine chest CT for staging of gastric cancer.

Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy.